Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1316

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 5
Chunk 1316
---
.895 per Pre-Funded Warrant and accompanying
Series A and Series B Warrants. The Private Placement closed on September 5, 2024, generating net proceeds to the Company of $3,414,502,
after deducting placement agent fees and offering expenses.

The September 2024 Pre-Funded Warrants have an
exercise price of $0.005 per share and were immediately exercisable on September 5, 2024 and may be exercised at any time until exercised
in full. The Series A and Series B Warrants have an exercise price of $6.90 per share and were exercisable beginning on the effective
date of stockholder approval to approve the issuance of the shares underlying the Series A and Series B Warrants and the September 2024
Agent Warrants, defined below, to comply with applicable listing rules and regulations of the Nasdaq Stock Market (“Stockholder
Approval”), which was later received on November 6, 2024 (the “Stockholder Approval Date”). The Series A Warrants expire
five years after the Stockholder Approval Date or November 6, 2029, and the Series B Warrants will expire 18 months after the Stockholder
Approval Date, or May 6, 2026. 

As compensation for acting as the placement agent
for the Private Placement, the Company issued to H.C. Wainwright & Co., LLC warrants to purchase up to 43,479 shares of stock (the
“September 2024 Agent Warrants”). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants,
except that the September 2024 Agent Warrants have an exercise price equal to $8.63 per share.

The following table presents a summary of the
activity for the Company’s equity-classified warrants during the year ended December 31, 2023:

     Number of Warrants   Weighted Average Exercise Price   Weighted Average Remaining Contractual Life (Years)   Total outstanding, December 31, 2022   -   $-    -   Reclassified from derivative liabilities   3,870    327.89    4.15   Granted   51,942    373.00    5.00   Exercised   (3,075)   368.16    5.00   Forfeited